Fig. 6
From: The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
The impact of propofol in combination with cisplatin and doxorubicin on the cell cycle profile in human ovarian cells. (A-B) After treating SKOV3 and OVCAR3 cells with concentrations of propofol (0 and 50 µg/ml) in combination with either 10 µM cisplatin or 1 µM doxorubicin for 24 h, PI staining was performed, and the cells were analyzed using flow cytometry. The bars represent the mean ± SD of three independent experiments. Statistical significance is indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001, determined using Student’s t-tests